15.03.09 22:45 Age: 361 days
Ipsogen announces the CE marking of its “ProfileQuant® WT1” kit
Category: Leukemia
- WT1 is a valuable biomarker in the prognosis and follow-up of Acute Myeloid Leukemia (AML) patients.
- The ProfileQuant® WT1 kit was developed and validated in the context of an international collaborative study coordinated by the European Leukemia Network (ELN) consortium.
- With its WT1 kit, Ipsogen continues its CE marking strategy and confirms its leadership position in molecular diagnosis of leukemia.
More
